Cephalon's Buchi Steps In To Fill Baldino's Big Shoes
This article was originally published in The Pink Sheet Daily
Executive Summary
Founder and CEO Frank Baldino is taking a temporary medical leave of absence, but the company says he will be back before the end of the year.
You may also be interested in...
Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology
Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority
Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology
The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.
Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology
The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.